Item 5.02 Resignation and Appointment of Certain Officers.
Effective June 16, 2021, the board of directors (the "Board") of the registrant
(the "Company") appointed Dr. Andrea Small-Howard President of the Company.
Also, effective June 16, 2021, John Poss resigned his position as President,
allowing for the appointment of Dr. Small-Howard. Mr. Poss will continue to
serve as Chief Executive Officer and as Chairman of the Board of Directors. Dr.
Small-Howard will also continue to serve as the Company's Chief Science Officer.
Dr. Small-Howard was appointed as the Chief Science Officer and as a member of
our board of directors on June 10, 2014, and she has served continuously in both
positions since that time. As the Chief Science Officer, Dr. Small-Howard's goal
has been to create and maintain a novel plant-inspired therapy pipeline based on
the Company's proprietary in silico technology suite, direct research &
development efforts, facilitate research and development partnerships, guide
product commercialization strategies, develop corporate messaging around our
novel drug discovery process, and make public presentations promoting the
Company's drug development programs and unique corporate strategy.
Dr. Andrea Small-Howard has more than 20 years of research experience; as well
as executive experience in the biopharmaceutical industry supervising research
and development, manufacturing, and quality control divisions in both the US and
China. In her biotechnology career, Dr. Small-Howard has taken novel biological
products from ideation through commercialization. Dr. Small-Howard has been
named an inventor on more than sixty patent applications and taken the lead in
obtaining regulatory approvals from the U.S. Food and Drug Administration ("US
FDA") and numerous international regulatory agencies. Dr. Small-Howard also
created commercialization strategies, advised on distribution relationships, led
branding committees, and supervised marketing materials. In one instance, Dr.
Small-Howard designed a commercialization strategy for an in-licensed cervical
cancer test. To that end, she developed technical product files in Korea with
the original manufacturer, sourced US raw materials, hired contract
manufacturers, created the US prototypes, and prepared regulatory filings. As VP
of Scientific Oversight at Radient Pharmaceuticals Corp., she provided strategic
product development and regulatory oversight across multiple international
Dr. Small-Howard has directed research efforts on cannabinoids for over 20
years, leading a project group dedicated to the study of cannabinoids in the
immune system as an NIH-funded post-doctoral fellow. In this work, she published
one of the earliest studies of cannabinoid impacts on pro-inflammatory
immunocytes. More recently she has contributed to published studies on consumer
protection issues surrounding 'medicinal' Cannabis chemovars in Nevada,
co-authored scholarly reviews on cannabinoids in heart disease and Parkinson's
disease, co-authored mechanistic studies on cannabinoid and terpene regulation
of ion channels, and co-authored an innovative study demonstrating the utility
of nanoparticles as delivery vehicles for Cannabis-derived therapeutic
For a four-year term (2012-2016), Dr. Small-Howard served on the Board of
Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan,
and independent organization based in Chicago that is committed to serving as a
catalyst for stimulating ideas, people, companies, and institutions to
collaborate and achieve excellence in healthcare innovation. Her board level
responsibilities at CHI included shaping and supporting the evolving mission of
this dynamic group. She also served on the planning committee for their annual
"Emerging Markets in the Life Sciences" seminar series, which ran for 5 years.
From July 2011 to June 2014, Dr. Small-Howard was the Founder and President of
International Biotechnology Solutions, a management consulting firm that created
customized, cost-effective commercialization solutions for viable yet abandoned
biopharmaceutical products. International Biotechnology Solutions provided
management consulting with a focus on assisting US biotech companies with
products that could be commercialized within the Asia-Pacific region. Dr.
Small-Howard successfully completed projects within the areas of business
development, corporate alliance building, product commercialization, due
diligence reporting on medical marijuana companies, corporate restructuring, and
management of successful fund-raising campaigns.
From June 2011 to March 2013, she served as a Director on the Board of Directors
(President for part of that time), for the Ceremax Investment Corporation. The
Ceremax Investment Group was established by members of the USC EMBA Class XXV to
pool its financial and intellectual resources to identify investment
opportunities. During her tenure at Ceremax, Dr. Small Howard reviewed and
approved capital and resource investments in promising start-up or scale-up
phase private companies.
From November, 2008 to July, 2011, Dr. Small-Howard served as the Vice President
of Scientific Oversight for the Radient Pharmaceutical Corporation, a
vertically-integrated biopharmaceutical research, development, and manufacturing
corporation with operations in both the US and China. Dr. Small-Howard provided
oversight for global product development in multiple international business
divisions. She authored and/or attained 12 patents & 3 trademarks on proprietary
cancer tests, cancer (gene) therapies, cosmeceuticals, and novel animal models.
She achieved numerous regulatory approvals for cancer tests, cancer therapies,
pharmaceuticals, and cosmeceutical products with the United States FDA, Health
Canada, and other foreign ministries of health. She initiated and/or nurtured
five international, collaborative, cancer research trial programs with
universities that yielded 7 publications supporting cancer products and
supervised the Quality Management Systems for an ISO 13485/cGMP compliant
medical device manufacturing facility in the US; as well as the regulated
manufacturing facilities in China. She also led and participated in internal and
US FDA, CDPH, CE Mark/ISO 13485, and CMDR audits of Radient's Quality Management
© Edgar Online, source Glimpses